Skip to main content
Top
Published in: BMC Public Health 1/2024

Open Access 01-12-2024 | Colorectal Cancer | Research

Efficient organized colorectal cancer screening in Shenzhen: a microsimulation modelling study

Authors: Minmin Zhu, Xuan Zhong, Tong Liao, Xiaolin Peng, Lin Lei, Ji Peng, Yong Cao

Published in: BMC Public Health | Issue 1/2024

Login to get access

Abstract

Background

Colorectal cancer (CRC) is a global health issue with noticeably high incidence and mortality. Microsimulation models offer a time-efficient method to dynamically analyze multiple screening strategies. The study aimed to identify the efficient organized CRC screening strategies for Shenzhen City.

Methods

A microsimulation model named CMOST was employed to simulate CRC screening among 1 million people without migration in Shenzhen, with two CRC developing pathways and real-world participation rates. Initial screening included the National Colorectal Polyp Care score (NCPCS), fecal immunochemical test (FIT), and risk-stratification model (RS model), followed by diagnostic colonoscopy for positive results. Several start-ages (40, 45, 50 years), stop-ages (70, 75, 80 years), and screening intervals (annual, biennial, triennial) were assessed for each strategy. The efficiency of CRC screening was assessed by number of colonoscopies versus life-years gained (LYG).

Results

The screening strategies reduced CRC lifetime incidence by 14–27 cases (30.9–59.0%) and mortality by 7–12 deaths (41.5–71.3%), yielded 83–155 LYG, while requiring 920 to 5901 colonoscopies per 1000 individuals. Out of 81 screening, 23 strategies were estimated efficient. Most of the efficient screening strategies started at age 40 (17 out of 23 strategies) and stopped at age 70 (13 out of 23 strategies). Predominant screening intervals identified were annual for NCPCS, biennial for FIT, and triennial for RS models. The incremental colonoscopies to LYG ratios of efficient screening increased with shorter intervals within the same test category. Compared with no screening, when screening at the same start-to-stop age and interval, the additional colonoscopies per LYG increased progressively for FIT, NCPCS and RS model.

Conclusion

This study identifies efficient CRC screening strategies for the average-risk population in Shenzhen. Most efficient screening strategies indeed start at age 40, but the optimal starting age depends on the chosen willingness-to-pay threshold. Within insufficient colonoscopy resources, efficient FIT and NCPCS screening strategies might be CRC initial screening strategies. We acknowledged the age-dependency bias of the results with NCPCS and RS.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
2.
go back to reference Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J. 2021;134(7):783–91.PubMedPubMedCentralCrossRef Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J. 2021;134(7):783–91.PubMedPubMedCentralCrossRef
3.
go back to reference Wang N, Liu J, Li X, Wang C, Zi H, Yang M, et al. An analysis of disease burden of colorectal cancer in China from 1990 to 2019. Chin J Evid Based Med. 2021;21(05):520–4.ADS Wang N, Liu J, Li X, Wang C, Zi H, Yang M, et al. An analysis of disease burden of colorectal cancer in China from 1990 to 2019. Chin J Evid Based Med. 2021;21(05):520–4.ADS
4.
go back to reference Ladabaum U, Dominitz JA, Kahi C, Schoen RE. Strategies for colorectal cancer screening. Gastroenterology. 2020;158(2):418–32.PubMedCrossRef Ladabaum U, Dominitz JA, Kahi C, Schoen RE. Strategies for colorectal cancer screening. Gastroenterology. 2020;158(2):418–32.PubMedCrossRef
6.
8.
go back to reference Liu F, Wang Y, Cai W, Liang L, Peng J, Lei L. The incidence and trend of colorectal cancer in Shenzhen City from 2001 to 2018. China Cancer. 2021;30(09):671–7. Liu F, Wang Y, Cai W, Liang L, Peng J, Lei L. The incidence and trend of colorectal cancer in Shenzhen City from 2001 to 2018. China Cancer. 2021;30(09):671–7.
9.
go back to reference Meester RGS, Peterse EFP, Knudsen AB, de Weerdt AC, Chen JC, Lietz AP, et al. Optimizing colorectal cancer screening by race and sex: microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline. Cancer. 2018;124(14):2974–85.PubMedCrossRef Meester RGS, Peterse EFP, Knudsen AB, de Weerdt AC, Chen JC, Lietz AP, et al. Optimizing colorectal cancer screening by race and sex: microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline. Cancer. 2018;124(14):2974–85.PubMedCrossRef
10.
go back to reference Knudsen AB, Rutter CM, Peterse EFP, Lietz AP, Seguin CL, Meester RGS, et al. Colorectal Cancer screening: an updated modeling study for the US preventive services task force. JAMA. 2021;325(19):1998–2011.PubMedPubMedCentralCrossRef Knudsen AB, Rutter CM, Peterse EFP, Lietz AP, Seguin CL, Meester RGS, et al. Colorectal Cancer screening: an updated modeling study for the US preventive services task force. JAMA. 2021;325(19):1998–2011.PubMedPubMedCentralCrossRef
11.
go back to reference Gauvreau CL, Fitzgerald NR, Memon S, Flanagan WM, Nadeau C, Asakawa K, et al. The OncoSim model: development and use for better decision-making in Canadian cancer control. Curr Oncol. 2017;24(6):401–6.PubMedPubMedCentralCrossRef Gauvreau CL, Fitzgerald NR, Memon S, Flanagan WM, Nadeau C, Asakawa K, et al. The OncoSim model: development and use for better decision-making in Canadian cancer control. Curr Oncol. 2017;24(6):401–6.PubMedPubMedCentralCrossRef
12.
go back to reference Gini A, van Ravesteyn NT, Jansen EEL, Heijnsdijk EAM, Senore C, Anttila A, et al. The EU-TOPIA evaluation tool: an online modelling-based tool for informing breast, cervical, and colorectal cancer screening decisions in Europe. Prev Med Rep. 2021;22:101392.PubMedPubMedCentralCrossRef Gini A, van Ravesteyn NT, Jansen EEL, Heijnsdijk EAM, Senore C, Anttila A, et al. The EU-TOPIA evaluation tool: an online modelling-based tool for informing breast, cervical, and colorectal cancer screening decisions in Europe. Prev Med Rep. 2021;22:101392.PubMedPubMedCentralCrossRef
13.
go back to reference Buskermolen M, Cenin DR, Helsingen LM, Guyatt G, Vandvik PO, Haug U, et al. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. BMJ. 2019;367:l5383.PubMedPubMedCentralCrossRef Buskermolen M, Cenin DR, Helsingen LM, Guyatt G, Vandvik PO, Haug U, et al. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. BMJ. 2019;367:l5383.PubMedPubMedCentralCrossRef
14.
go back to reference Helsingen LM, Vandvik PO, Jodal HC, Agoritsas T, Lytvyn L, Anderson JC, et al. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. BMJ. 2019;367:l5515.PubMedCrossRef Helsingen LM, Vandvik PO, Jodal HC, Agoritsas T, Lytvyn L, Anderson JC, et al. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. BMJ. 2019;367:l5515.PubMedCrossRef
15.
go back to reference Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250–81.PubMedCrossRef Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250–81.PubMedCrossRef
16.
go back to reference Cenin D, Li P, Wang J, de Jonge L, Yan B, Tao S, et al. Optimising colorectal cancer screening in Shanghai, China: a modelling study. BMJ Open. 2022;12(5):e048156.PubMedPubMedCentralCrossRef Cenin D, Li P, Wang J, de Jonge L, Yan B, Tao S, et al. Optimising colorectal cancer screening in Shanghai, China: a modelling study. BMJ Open. 2022;12(5):e048156.PubMedPubMedCentralCrossRef
17.
go back to reference Wang J, de Jonge L, Cenin DR, Li P, Tao S, Yang C, et al. Cost-effectiveness analysis of colorectal cancer screening in Shanghai, China: a modelling study. Prev Med Rep. 2022;29:101891.PubMedPubMedCentralCrossRef Wang J, de Jonge L, Cenin DR, Li P, Tao S, Yang C, et al. Cost-effectiveness analysis of colorectal cancer screening in Shanghai, China: a modelling study. Prev Med Rep. 2022;29:101891.PubMedPubMedCentralCrossRef
18.
go back to reference Prakash MK, Lang B, Heinrich H, Valli PV, Bauerfeind P, Sonnenberg A, et al. CMOST: an open-source framework for the microsimulation of colorectal cancer screening strategies. BMC Med Inform Decis Mak. 2017;17(1):80.PubMedPubMedCentralCrossRef Prakash MK, Lang B, Heinrich H, Valli PV, Bauerfeind P, Sonnenberg A, et al. CMOST: an open-source framework for the microsimulation of colorectal cancer screening strategies. BMC Med Inform Decis Mak. 2017;17(1):80.PubMedPubMedCentralCrossRef
19.
go back to reference Deibel A, Deng L, Cheng CY, Schlander M, Ran T, Lang B, et al. Evaluating key characteristics of ideal colorectal cancer screening modalities: the microsimulation approach. Gastrointest Endosc. 2021;94(2):379–90.e7.PubMedCrossRef Deibel A, Deng L, Cheng CY, Schlander M, Ran T, Lang B, et al. Evaluating key characteristics of ideal colorectal cancer screening modalities: the microsimulation approach. Gastrointest Endosc. 2021;94(2):379–90.e7.PubMedCrossRef
20.
go back to reference Chen H, Li N, Ren J, Feng X, Lyu Z, Wei L, et al. Participation and yield of a population-based colorectal cancer screening programme in China. Gut. 2019;68(8):1450–7.PubMedCrossRef Chen H, Li N, Ren J, Feng X, Lyu Z, Wei L, et al. Participation and yield of a population-based colorectal cancer screening programme in China. Gut. 2019;68(8):1450–7.PubMedCrossRef
22.
go back to reference Gong Y, Wu C, Zhang M, Peng P, Gu K, Bao P, et al. Colorectal cancer survival analysis in major areas in Shanghai China. Chin Oncol. 2015;25(7):497–504. Gong Y, Wu C, Zhang M, Peng P, Gu K, Bao P, et al. Colorectal cancer survival analysis in major areas in Shanghai China. Chin Oncol. 2015;25(7):497–504.
23.
go back to reference Cause of death surveillance data set in China. 2020. Beijing: China Science and Technology Press. Cause of death surveillance data set in China. 2020. Beijing: China Science and Technology Press.
24.
go back to reference Zhao S, Wang S, Pan P, Xia T, Wang R, Cai Q, et al. FIT-based risk-stratification model effectively screens colorectal neoplasia and early-onset colorectal cancer in Chinese population: a nationwide multicenter prospective study. J Hematol Oncol. 2022;15(1):162.PubMedPubMedCentralCrossRef Zhao S, Wang S, Pan P, Xia T, Wang R, Cai Q, et al. FIT-based risk-stratification model effectively screens colorectal neoplasia and early-onset colorectal cancer in Chinese population: a nationwide multicenter prospective study. J Hematol Oncol. 2022;15(1):162.PubMedPubMedCentralCrossRef
25.
go back to reference Lu M, Zhang YH, Lu B, Cai J, Liu CC, Chen HD, et al. Head-to-head comparison of the test performance of self-administered qualitative vs. laboratory-based quantitative fecal immunochemical tests in detecting colorectal neoplasm. Chin Med J. 2021;134(11):1335–44.PubMedPubMedCentralCrossRef Lu M, Zhang YH, Lu B, Cai J, Liu CC, Chen HD, et al. Head-to-head comparison of the test performance of self-administered qualitative vs. laboratory-based quantitative fecal immunochemical tests in detecting colorectal neoplasm. Chin Med J. 2021;134(11):1335–44.PubMedPubMedCentralCrossRef
26.
go back to reference Chen H, Lu M, Liu C, Zou S, Du L, Liao X, et al. Comparative evaluation of participation and diagnostic yield of colonoscopy vs fecal immunochemical test vs risk-adapted screening in colorectal Cancer screening: interim analysis of a multicenter randomized controlled trial (TARGET-C). Am J Gastroenterol. 2020;115(8):1264–74.PubMedCrossRef Chen H, Lu M, Liu C, Zou S, Du L, Liao X, et al. Comparative evaluation of participation and diagnostic yield of colonoscopy vs fecal immunochemical test vs risk-adapted screening in colorectal Cancer screening: interim analysis of a multicenter randomized controlled trial (TARGET-C). Am J Gastroenterol. 2020;115(8):1264–74.PubMedCrossRef
27.
go back to reference Panwar A, Olfati M, Pant M, Snasel V. A review on the 40 years of existence of data envelopment analysis models: historic development and current trends. Arch Comput Methods Eng. 2022;29(7):5397–426.PubMedPubMedCentralCrossRef Panwar A, Olfati M, Pant M, Snasel V. A review on the 40 years of existence of data envelopment analysis models: historic development and current trends. Arch Comput Methods Eng. 2022;29(7):5397–426.PubMedPubMedCentralCrossRef
28.
go back to reference Knudsen AB, Zauber AG, Rutter CM, Naber SK, Doria-Rose VP, Pabiniak C, et al. Estimation of benefits, burden, and harms of colorectal Cancer screening strategies: modeling study for the US preventive services task force. JAMA. 2016;315(23):2595–609.PubMedPubMedCentralCrossRef Knudsen AB, Zauber AG, Rutter CM, Naber SK, Doria-Rose VP, Pabiniak C, et al. Estimation of benefits, burden, and harms of colorectal Cancer screening strategies: modeling study for the US preventive services task force. JAMA. 2016;315(23):2595–609.PubMedPubMedCentralCrossRef
29.
go back to reference Khalid-de Bakker C, Jonkers D, Smits K, Mesters I, Masclee A, Stockbrugger R. Participation in colorectal cancer screening trials after first-time invitation: a systematic review. Endos. 2011;43(12):1059–86.CrossRef Khalid-de Bakker C, Jonkers D, Smits K, Mesters I, Masclee A, Stockbrugger R. Participation in colorectal cancer screening trials after first-time invitation: a systematic review. Endos. 2011;43(12):1059–86.CrossRef
30.
go back to reference Lin G, Feng Z, Liu H, Li Y, Nie Y, Liang Y, et al. Mass screening for colorectal cancer in a population of two million older adults in Guangzhou, China. Sci Rep. 2019;9(1):10424.ADSPubMedPubMedCentralCrossRef Lin G, Feng Z, Liu H, Li Y, Nie Y, Liang Y, et al. Mass screening for colorectal cancer in a population of two million older adults in Guangzhou, China. Sci Rep. 2019;9(1):10424.ADSPubMedPubMedCentralCrossRef
31.
go back to reference Tan S, Yang Y, Gui K, Yang C, Gong Y, Wu W, et al. Comprehensive analysis of colonoscopy compliance for colorectal cancer screening cross populations in China. Chin J Cancer Prev Treat. 2021;28(17):1283–9. Tan S, Yang Y, Gui K, Yang C, Gong Y, Wu W, et al. Comprehensive analysis of colonoscopy compliance for colorectal cancer screening cross populations in China. Chin J Cancer Prev Treat. 2021;28(17):1283–9.
32.
go back to reference National Cancer Center, China, Expert Group of the Development of China Guideline for the Screening, Early Detection and Early Treatment of Colorectal Cancer. China guideline for the screening, early detection and early treatment of colorectal cancer (2020, Beijing). Zhonghua Zhong Liu Za Zhi. 2021;43(1):16–38. Chinese. https://doi.org/10.3760/cma.j.cn112152-20210105-00010. National Cancer Center, China, Expert Group of the Development of China Guideline for the Screening, Early Detection and Early Treatment of Colorectal Cancer. China guideline for the screening, early detection and early treatment of colorectal cancer (2020, Beijing). Zhonghua Zhong Liu Za Zhi. 2021;43(1):16–38. Chinese. https://​doi.​org/​10.​3760/​cma.​j.​cn112152-20210105-00010.
33.
go back to reference Lu B, Wang L, Lu M, Zhang Y, Cai J, Luo C, et al. Microsimulation model for prevention and intervention of Coloretal Cancer in China (MIMIC-CRC): development, calibration, validation, and application. Front Oncol. 2022;12:883401.PubMedPubMedCentralCrossRef Lu B, Wang L, Lu M, Zhang Y, Cai J, Luo C, et al. Microsimulation model for prevention and intervention of Coloretal Cancer in China (MIMIC-CRC): development, calibration, validation, and application. Front Oncol. 2022;12:883401.PubMedPubMedCentralCrossRef
34.
go back to reference Zhou Q, Li HL, Li Y, Gu YT, Liang YR, Liu HZ, et al. Cost-effectiveness analysis of different screening strategies for colorectal cancer in Guangzhou, southern China: a Markov simulation analysis based on natural community screening results. BMJ Open. 2021;11(9):e049581.PubMedPubMedCentralCrossRef Zhou Q, Li HL, Li Y, Gu YT, Liang YR, Liu HZ, et al. Cost-effectiveness analysis of different screening strategies for colorectal cancer in Guangzhou, southern China: a Markov simulation analysis based on natural community screening results. BMJ Open. 2021;11(9):e049581.PubMedPubMedCentralCrossRef
35.
go back to reference Howren A, Sayre EC, Loree JM, Gill S, Brown CJ, Raval MJ, et al. Trends in the incidence of young-onset colorectal cancer with a focus on years approaching screening age: a population-based longitudinal study. J Natl Cancer Inst. 2021;113(7):863–8.PubMedPubMedCentralCrossRef Howren A, Sayre EC, Loree JM, Gill S, Brown CJ, Raval MJ, et al. Trends in the incidence of young-onset colorectal cancer with a focus on years approaching screening age: a population-based longitudinal study. J Natl Cancer Inst. 2021;113(7):863–8.PubMedPubMedCentralCrossRef
36.
go back to reference Stoffel EM, Murphy CC. Epidemiology and mechanisms of the increasing incidence of Colon and Rectal cancers in young adults. Gastro. 2020;158(2):341–53.CrossRef Stoffel EM, Murphy CC. Epidemiology and mechanisms of the increasing incidence of Colon and Rectal cancers in young adults. Gastro. 2020;158(2):341–53.CrossRef
37.
go back to reference Yeoh KG, Ho KY, Chiu HM, Zhu F, Ching JY, Wu DC, et al. The Asia-Pacific colorectal screening score: a validated tool that stratifies risk for colorectal advanced neoplasia in asymptomatic Asian subjects. Gut. 2011;60(9):1236–41.PubMedCrossRef Yeoh KG, Ho KY, Chiu HM, Zhu F, Ching JY, Wu DC, et al. The Asia-Pacific colorectal screening score: a validated tool that stratifies risk for colorectal advanced neoplasia in asymptomatic Asian subjects. Gut. 2011;60(9):1236–41.PubMedCrossRef
38.
go back to reference Sung JJY, Wong MCS, Lam TYT, Tsoi KKF, Chan VCW, Cheung W, et al. A modified colorectal screening score for prediction of advanced neoplasia: a prospective study of 5744 subjects. J Gastroenterol Hepatol. 2018;33(1):187–94.PubMedCrossRef Sung JJY, Wong MCS, Lam TYT, Tsoi KKF, Chan VCW, Cheung W, et al. A modified colorectal screening score for prediction of advanced neoplasia: a prospective study of 5744 subjects. J Gastroenterol Hepatol. 2018;33(1):187–94.PubMedCrossRef
39.
go back to reference Ye D, Huang Q, Li Q, Jiang X, Mamat M, Tang M, et al. Comparative evaluation of preliminary screening methods for colorectal cancer in a mass program. Dig Dis Sci. 2017;62(9):2532–41.PubMedCrossRef Ye D, Huang Q, Li Q, Jiang X, Mamat M, Tang M, et al. Comparative evaluation of preliminary screening methods for colorectal cancer in a mass program. Dig Dis Sci. 2017;62(9):2532–41.PubMedCrossRef
40.
go back to reference Zhu N, Huang YQ, Song YM, Zhang SZ, Zheng S, Yuan Y. Efficacy comparison among high risk factors questionnaire and Asia-Pacific colorectal screening score and their combinations with fecal immunochemical test in screening advanced colorectal tumor. Zhonghua Wei Chang Wai Ke Za Zhi. 2022;25(7):612–20.PubMed Zhu N, Huang YQ, Song YM, Zhang SZ, Zheng S, Yuan Y. Efficacy comparison among high risk factors questionnaire and Asia-Pacific colorectal screening score and their combinations with fecal immunochemical test in screening advanced colorectal tumor. Zhonghua Wei Chang Wai Ke Za Zhi. 2022;25(7):612–20.PubMed
41.
go back to reference Zhou H, Zhang X, Shen ZH, Chen XB, Zhao GQ, Lin YP, et al. Screening of colorectal cancer in Kunming urban residents from 2014 to 2017. Zhonghua Weichang Waike Zazhi. 2019;22(11):1058–63.PubMed Zhou H, Zhang X, Shen ZH, Chen XB, Zhao GQ, Lin YP, et al. Screening of colorectal cancer in Kunming urban residents from 2014 to 2017. Zhonghua Weichang Waike Zazhi. 2019;22(11):1058–63.PubMed
42.
go back to reference Cai QC, Yu ED, Xiao Y, Bai WY, Chen X, He LP, et al. Derivation and validation of a prediction rule for estimating advanced colorectal neoplasm risk in average-risk Chinese. Am J Epidemiol. 2012;175(6):584–93.PubMedCrossRef Cai QC, Yu ED, Xiao Y, Bai WY, Chen X, He LP, et al. Derivation and validation of a prediction rule for estimating advanced colorectal neoplasm risk in average-risk Chinese. Am J Epidemiol. 2012;175(6):584–93.PubMedCrossRef
43.
go back to reference Wu W, Huang J, Yang Y, Gu K, Luu HN, Tan S, et al. Adherence to colonoscopy in cascade screening of colorectal cancer: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37(4):620–31.PubMedCrossRef Wu W, Huang J, Yang Y, Gu K, Luu HN, Tan S, et al. Adherence to colonoscopy in cascade screening of colorectal cancer: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37(4):620–31.PubMedCrossRef
44.
go back to reference Fisher DA, Princic N, Miller-Wilson LA, Wilson K, DeYoung K, Ozbay AB, et al. Adherence to fecal immunochemical test screening among adults at average risk for colorectal cancer. Int J Color Dis. 2022;37(3):719–21.CrossRef Fisher DA, Princic N, Miller-Wilson LA, Wilson K, DeYoung K, Ozbay AB, et al. Adherence to fecal immunochemical test screening among adults at average risk for colorectal cancer. Int J Color Dis. 2022;37(3):719–21.CrossRef
45.
go back to reference van Roon AH, Goede SL, van Ballegooijen M, van Vuuren AJ, Looman CW, Biermann K, et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut. 2013;62(3):409–15.PubMedCrossRef van Roon AH, Goede SL, van Ballegooijen M, van Vuuren AJ, Looman CW, Biermann K, et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut. 2013;62(3):409–15.PubMedCrossRef
46.
go back to reference Zhao S, Wang S, Pan P, Xia T, Chang X, Yang X, et al. Magnitude, risk factors, and factors associated with adenoma miss rate of tandem colonoscopy: a systematic review and meta-analysis. Gastro. 2019;156(6):1661–74 e1611.CrossRef Zhao S, Wang S, Pan P, Xia T, Chang X, Yang X, et al. Magnitude, risk factors, and factors associated with adenoma miss rate of tandem colonoscopy: a systematic review and meta-analysis. Gastro. 2019;156(6):1661–74 e1611.CrossRef
Metadata
Title
Efficient organized colorectal cancer screening in Shenzhen: a microsimulation modelling study
Authors
Minmin Zhu
Xuan Zhong
Tong Liao
Xiaolin Peng
Lin Lei
Ji Peng
Yong Cao
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2024
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-024-18201-w

Other articles of this Issue 1/2024

BMC Public Health 1/2024 Go to the issue